TY - JOUR
T1 - Non-melanoma skin cancers
T2 - physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments
AU - Souto, Eliana B.
AU - da Ana, Raquel
AU - Vieira, Vânia
AU - Fangueiro, Joana F.
AU - Dias-Ferreira, João
AU - Cano, Amanda
AU - Zielińska, Aleksandra
AU - Silva, Amélia M.
AU - Staszewski, Rafał
AU - Karczewski, Jacek
N1 - Funding Information:
Authors wish to acknowledge the National Science Centre within the MINIATURA 4 for a single research activity carried out by Dr. Aleksandra Zielińska (grant no: 2020/04/X/ST5/00789), the Institute of Human Genetics, Polish Academy of Sciences by the internal grant for the implementation of a single scientific activity, and the Poznan University of Medical Sciences. Authors also wish to thank the Portuguese Science and Technology Foundation (FCT) from the Ministry of Science and Technology (MCTES) for sponsoring the project UIDB/04033/2020 (CITAB), co-funded by European Funds (PRODER/COMPETE) and FEDER, under the Partnership Agreement PT2020.
Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - Non-melanoma carcinoma has high incidence rates and has two most common subtypes: basal cell carcinoma and squamous cell carcinoma. This type of carcinoma is usually not fatal; however, it can destroy sensory organs such as the nose, ears, and lips. The treatment of these injuries using non-invasive methods is thus strongly recommended. Some treatments for non-melanoma carcinoma are already well defined, such as surgery, cryosurgery, curettage and electrode section, and radiotherapy; however, these conventional treatments cause inflammation and scarring. In the non-surgical treatment of non-melanoma carcinoma, the topical administration of chemotherapeutic drugs contributes for an effective treatment with reduced side effects. However, the penetration of anticancer drugs in the deeper layers of the skin is required. Lipid delivery systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers) have been developed to overcome epidermal barrier of the skin and to allow the drugs to reach tumor cells. These lipid nanoparticles contribute to control the release profile of the loaded chemotherapeutic drugs, maintaining their stability and increasing death of tumor cells. In this review, the characteristics of non-melanoma carcinoma will be discussed, describing the main existing treatments, together with the contribution of lipid delivery systems as an innovative approach to increase the effectiveness of topical therapies for non-melanoma carcinomas.
AB - Non-melanoma carcinoma has high incidence rates and has two most common subtypes: basal cell carcinoma and squamous cell carcinoma. This type of carcinoma is usually not fatal; however, it can destroy sensory organs such as the nose, ears, and lips. The treatment of these injuries using non-invasive methods is thus strongly recommended. Some treatments for non-melanoma carcinoma are already well defined, such as surgery, cryosurgery, curettage and electrode section, and radiotherapy; however, these conventional treatments cause inflammation and scarring. In the non-surgical treatment of non-melanoma carcinoma, the topical administration of chemotherapeutic drugs contributes for an effective treatment with reduced side effects. However, the penetration of anticancer drugs in the deeper layers of the skin is required. Lipid delivery systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers) have been developed to overcome epidermal barrier of the skin and to allow the drugs to reach tumor cells. These lipid nanoparticles contribute to control the release profile of the loaded chemotherapeutic drugs, maintaining their stability and increasing death of tumor cells. In this review, the characteristics of non-melanoma carcinoma will be discussed, describing the main existing treatments, together with the contribution of lipid delivery systems as an innovative approach to increase the effectiveness of topical therapies for non-melanoma carcinomas.
KW - Basal cell carcinoma
KW - Liposomes
KW - Nanostructured lipid carriers
KW - Solid lipid nanoparticles
KW - Squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85131064287&partnerID=8YFLogxK
U2 - 10.1016/j.neo.2022.100810
DO - 10.1016/j.neo.2022.100810
M3 - Review article
C2 - 35649306
AN - SCOPUS:85131064287
SN - 1522-8002
VL - 30
JO - Neoplasia (United States)
JF - Neoplasia (United States)
M1 - 100810
ER -
